Alzheimer’s Research

Reduced cognitive function without substantial memory complaints may be a normal part of aging and not an early sign of Alzheimer’s disease or other dementias, investigators say.

Users of sildenafil are 69% less likely to develop Alzheimer’s disease than their peers who do not use the drug, investigators report. A clinical trial to confirm its benefits for Alzheimer’s patients...

Researchers from the University of California, Riverside say they have uncovered a reason why some people with plaques and tangles in their brains do not develop Alzheimer’s disease.

Sixteen participants with early, symptomatic Alzheimer’s will receive doses of a vaccine containing the immune-modulating drug Protollin. Nasal delivery has shown promise as a way to eliminate beta amyloid...

The experimental Alzheimer’s drug gantenerumab is the “first and only” anti-amyloid antibody being investigated for subcutaneous administration and could potentially be given to patients...

Drugmakers Eisai and Biogen are putting the Food and Drug Administration to the test with a request to approve a second Alzheimer’s drug that works like aducanumab (Aduhelm), the new, yet controversial,...

People with early Alzheimer’s who are treated with the drug donepezil maintain mitochondrial function in their muscles when compared to their untreated peers, researchers report.

Treatments targeting inflammation could help reverse or at least slow the accumulation of pathologic tau protein in the brain — benefitting people with early dementia, investigators say.

A new paper showcases the results of 11 years of federal investment in dementia research, including advancements in care intervention, diagnostics and therapeutics.

The Alzheimer’s disease-modifying drug donanemab is on track to be considered for full FDA approval by 2022, its developer said.